Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, Fojo T. Wilkerson J, et al. Lancet Oncol. 2017 Jan;18(1):143-154. doi: 10.1016/S1470-2045(16)30633-7. Epub 2016 Dec 13. Lancet Oncol. 2017. PMID: 27979599
A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide.
Leuva H, Sigel K, Zhou M, Wilkerson J, Aggen DH, Park YA, Anderson CB, Hsu TM, Langhoff E, McWilliams G, Drake CG, Simon R, Bates SE, Fojo T. Leuva H, et al. Among authors: wilkerson j. Semin Oncol. 2019 Aug-Oct;46(4-5):351-361. doi: 10.1053/j.seminoncol.2019.11.004. Epub 2019 Nov 16. Semin Oncol. 2019. PMID: 31757478 Review.
Bevacizumab and breast cancer: the E2100 outlier.
Fojo T, Wilkerson J. Fojo T, et al. Among authors: wilkerson j. Lancet Oncol. 2010 Dec;11(12):1117-9. doi: 10.1016/S1470-2045(10)70259-X. Lancet Oncol. 2010. PMID: 21126685 No abstract available.
Hazard ratios in cancer clinical trials--a primer.
Blagoev KB, Wilkerson J, Fojo T. Blagoev KB, et al. Among authors: wilkerson j. Nat Rev Clin Oncol. 2012 Jan 31;9(3):178-83. doi: 10.1038/nrclinonc.2011.217. Nat Rev Clin Oncol. 2012. PMID: 22290283 Free PMC article. Review.
450 results